Company presenting at Techknow in Sydney (today)/ Melbourne (tomorrow), page-55

Not sure of which deal you mean, but am sure there are, but I’d assume the signal from the data was much more definitive than ours?

I can see why MT would not want to licence, we don’t need the capital anymore and he’s confident, so don’t share the winnings.

A clearer indication of merit, is Healey willingness to take us. ODD to a certain extent. Healey uses up resources, soaks up trial capacity, and the KOL in the field are recommending further investigation over other drugs.

The writing on the wall is becoming clearer imho.